Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 15734327 | BLEOMYCIN FOR MIMICKING THE EFFECT OF IONIZING RADIATIONS ON T CELLS | December 2020 | April 2023 | Allow | 28 | 2 | 0 | Yes | No |
| 16952635 | COMPOSITION FOR PREVENTING, RELIEVING OR TREATING CLIMACTERIC DISORDERS COMPRISING LACTIC ACID BACTERIA AND PREBIOTICS | November 2020 | June 2023 | Allow | 31 | 1 | 0 | Yes | No |
| 17056451 | ELECTROPHORETIC BIOLOGICAL SAMPLE STAINING METHOD AND STAINING APPARATUS USING | November 2020 | February 2025 | Abandon | 51 | 2 | 1 | No | No |
| 17081844 | METHOD AND AN APPARATUS FOR TREATING PLANT BASED RAW MATERIAL WITH AN ENZYMATIC HYDROLYSIS | October 2020 | May 2024 | Allow | 42 | 1 | 0 | Yes | No |
| 16980189 | HIGH DENSITY 3D HEPATOCYTE SPHEROID PLATFORM FOR DRUG ADME STUDIES | September 2020 | May 2025 | Abandon | 56 | 3 | 0 | No | No |
| 16991502 | CHROMOGENIC MEDIUM FOR THE DETECTION AND IDENTIFICATION OF VANCOMYCIN RESISTANT ENTEROCOCCI AND METHOD THEREFOR | August 2020 | December 2022 | Allow | 28 | 0 | 0 | Yes | No |
| 16989718 | METHODS OF RECOVERING OIL FROM MICROORGANISMS | August 2020 | June 2023 | Allow | 34 | 2 | 0 | Yes | No |
| 16935837 | PROBIOTIC THERAPIES FOR TREATING RETT SYNDROME | July 2020 | September 2023 | Allow | 38 | 2 | 0 | Yes | No |
| 16915851 | METHOD FOR CLASSIFYING/COUNTING LEUKOCYTES, REAGENT KIT FOR CLASSIFYING LEUKOCYTES, AND REAGENT FOR CLASSIFYING LEUKOCYTES | June 2020 | April 2024 | Allow | 46 | 3 | 1 | Yes | No |
| 16954659 | PROBIOTICS FOR COGNITIVE AND MENTAL HEALTH | June 2020 | March 2024 | Abandon | 45 | 1 | 1 | No | No |
| 16852236 | METHODS FOR THE ISOLATION OF MICROBES WITH ENHANCED PERSISTANCE AND COMPOSITIONS WITH SUCH MICROBES | April 2020 | April 2023 | Allow | 36 | 2 | 1 | Yes | No |
| 16832010 | INCORPORATION OF PHOSPHATIDYLCHOLINE IN A MEDIA COMPOSITION | March 2020 | October 2023 | Abandon | 43 | 5 | 0 | No | No |
| 16648175 | Composition for Increasing Muscle Mass | March 2020 | March 2024 | Abandon | 48 | 5 | 0 | Yes | No |
| 16816403 | CLEANING COMPOSITIONS COMPRISING ENZYMES | March 2020 | December 2023 | Abandon | 45 | 4 | 1 | No | Yes |
| 16644769 | METHOD FOR DIAGNOSING PANCREATIC CANCER USING METHIONYL-TRNA SYNTHETASE, AND PANCREATIC CANCER DIAGNOSTIC KIT USING SAME | March 2020 | June 2024 | Abandon | 51 | 2 | 1 | No | No |
| 16641622 | INACTIVATED BACILLUS COAGULANTS AND USES THEREOF FOR REDUCING STRESS | February 2020 | April 2025 | Abandon | 60 | 4 | 0 | No | Yes |
| 16799369 | HISTOLOGICAL SPECIMEN TREATMENT | February 2020 | December 2023 | Allow | 45 | 5 | 1 | Yes | No |
| 16637283 | A METHOD FOR REMEDIATION OF CONTAMINATED LANDS | February 2020 | April 2021 | Allow | 14 | 5 | 0 | Yes | No |
| 16635012 | BIOMARKERS IN EX VIVO LUNG PERFUSION (EVLP) PERFUSATE | January 2020 | April 2025 | Abandon | 60 | 5 | 1 | No | No |
| 16743304 | Methods for Localized Modification of Tissue Products | January 2020 | August 2022 | Abandon | 31 | 1 | 0 | No | No |
| 16724333 | IN VITRO BILIARY EXCRETION ASSAY | December 2019 | August 2022 | Abandon | 32 | 1 | 0 | No | No |
| 16723723 | USE OF AKKERMANSIA FOR TREATING METABOLIC DISORDERS | December 2019 | January 2021 | Abandon | 13 | 0 | 0 | No | No |
| 16723720 | USE OF AKKERMANSIA FOR TREATING METABOLIC DISORDERS | December 2019 | January 2021 | Abandon | 13 | 0 | 0 | No | No |
| 16709238 | USE OF AKKERMANSIA FOR TREATING METABOLIC DISORDERS | December 2019 | August 2020 | Abandon | 8 | 1 | 0 | No | No |
| 16709232 | USE OF AKKERMANSIA FOR TREATING METABOLIC DISORDERS | December 2019 | September 2020 | Abandon | 10 | 1 | 0 | No | No |
| 16698116 | METHOD, COMPOSITION, AND ARTICLE OF MANUFACTURE FOR PROVIDING ALPHA-1 ANTITRYPSIN | November 2019 | November 2023 | Abandon | 48 | 3 | 0 | No | No |
| 16690238 | MULTI-COMPONENT DETERGENTS OR CLEANSERS CONTAINING A QUINONE OXIDOREDUCTASE | November 2019 | January 2023 | Abandon | 38 | 2 | 1 | No | No |
| 16496971 | URINE FLOW CYTOMETRY AS BIOMARKER OF RENAL DISEASES | September 2019 | February 2023 | Abandon | 41 | 0 | 1 | No | No |
| 16496719 | A NOVEL PROBIOTIC LACTOBACILLUS CASEI STRAIN AND ITS USES | September 2019 | July 2023 | Allow | 45 | 4 | 1 | Yes | No |
| 16530502 | CARBON MONOXIDE AND CARBON DIOXIDE BIOCONVERSION PROCESS | August 2019 | July 2023 | Allow | 48 | 2 | 1 | Yes | No |
| 16530481 | CARBON DIOXIDE BIOCONVERSION PROCESS | August 2019 | June 2023 | Allow | 46 | 2 | 1 | Yes | No |
| 16520366 | COMPOSITE PROBIOTICS AND USE THEREOF | July 2019 | May 2022 | Allow | 34 | 2 | 1 | Yes | No |
| 16478001 | METHODS FOR IMPROVING FERTILITY IN ARTIFICIAL INSEMINATION | July 2019 | June 2023 | Abandon | 47 | 2 | 1 | No | No |
| 16474803 | A BLOOD COAGULATION FACTOR REPLACEMENT PRODUCT FOR USE IN THE TREATMENT OR PROPHYLAXIS OF BLEEDINGS | June 2019 | May 2023 | Allow | 46 | 2 | 1 | Yes | No |
| 16456972 | IN-VITRO METHODS FOR CLASSIFYING DRUGS ACCORDING TO THEIR POTENTIAL TO CAUSE LIVER CELL INJURY | June 2019 | February 2023 | Abandon | 44 | 1 | 1 | No | No |
| 16465320 | METHODS OF ENHANCING THE POTENCY OF INCRETIN-BASED DRUGS IN SUBJECTS IN NEED THEREOF | May 2019 | November 2021 | Allow | 30 | 2 | 1 | Yes | No |
| 16422311 | METHODS FOR TREATING AUTISM SPECTRUM DISORDER AND ASSOCIATED SYMPTOMS | May 2019 | August 2022 | Abandon | 39 | 2 | 1 | Yes | No |
| 16421068 | PHARMACEUTICAL COMPOSITIONS OF LIPASE-CONTAINING PRODUCTS, IN PARTICULAR OF PANCREATIN | May 2019 | January 2022 | Abandon | 32 | 1 | 0 | No | No |
| 16349033 | Competition Test of an Enzyme Substrate with Internal Compensation for Enzyme Activity | May 2019 | September 2022 | Abandon | 41 | 2 | 1 | No | No |
| 16348542 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | May 2019 | October 2022 | Abandon | 41 | 2 | 1 | No | No |
| 16348252 | AUXOTROPHIC SELECTION SYSTEM | May 2019 | July 2023 | Abandon | 51 | 3 | 1 | No | No |
| 16285088 | USE OF AKKERMANSIA FOR TREATING METABOLIC DISORDERS | May 2019 | January 2021 | Abandon | 22 | 0 | 1 | No | No |
| 16403095 | USE OF PURIFIED 2'-FUCOSYLLACTOSE, 3-FUCOSYLLACTOSE AND LACTODIFUCOTETRAOSE AS PREBIOTICS | May 2019 | May 2024 | Abandon | 60 | 4 | 1 | No | No |
| 16393684 | FATTY LIVER AND LIVER FIBROSIS EVALUATION SYSTEM BASED ON IMPEDANCE | April 2019 | March 2023 | Abandon | 47 | 1 | 1 | No | No |
| 16343696 | AGENT ACTING ON TRANSCELLULAR ION TRANSPORTER IN INTESTINAL TRACT, AGENT FOR ACTIVATING CHLORIDE CHANNEL, AGENT FOR PREVENTING OR TREATING RENAL DISEASE, OR AGENT FOR PROMOTING DEFECATION | April 2019 | April 2022 | Allow | 36 | 3 | 0 | Yes | No |
| 16384703 | PHARMACEUTICAL COMPOSITION CONTAINING DEOXYCHOLIC ACID | April 2019 | September 2023 | Abandon | 53 | 5 | 0 | No | No |
| 16379276 | METHODS OF REMOVING ALPHA-GALACTOSE | April 2019 | January 2022 | Abandon | 34 | 2 | 0 | No | No |
| 16377041 | METHOD FOR PREPARING CORNEAL TISSUE | April 2019 | May 2022 | Abandon | 37 | 3 | 0 | Yes | No |
| 16335852 | Process of Converting Carbon Dioxide Using Combination of Carbon Dioxide Mineralization Process and Metabolism of Sulfur-Oxidizing Microorganisms | March 2019 | August 2023 | Allow | 53 | 4 | 1 | Yes | No |
| 16334623 | A DETERGENT PRODUCT FOR COSMETIC USE | March 2019 | June 2021 | Allow | 27 | 2 | 0 | Yes | No |
| 16329483 | METHOD FOR CULTURING PHOTOSYNTHETIC MICROALGAE | February 2019 | June 2021 | Abandon | 28 | 1 | 0 | Yes | No |
| 16270415 | SYSTEM AND METHOD FOR SEQUESTERING SUBSTANCES IN BULK LIQUIDS | February 2019 | November 2020 | Allow | 21 | 0 | 0 | Yes | No |
| 16266653 | MICROORGANISMS INHIBITING THE FORMATION OF FOOT MALODOR | February 2019 | December 2021 | Abandon | 35 | 1 | 1 | No | No |
| 16262180 | ADAMTS13-CONTAINING COMPOSITIONS HAVING THROMBOLYTIC ACTIVITY | January 2019 | May 2021 | Allow | 27 | 1 | 1 | Yes | No |
| 16261633 | COMPLEX ENZYME-CONTAINED FUNCTIONAL ORE POWDER AND PROCESS FOR PRODUCING THE SAME | January 2019 | May 2023 | Abandon | 52 | 2 | 1 | No | Yes |
| 16256638 | PROCESSES FOR PRODUCING COMPOSITIONS WITH IMPROVED SAFETY PROFILE HAVING LIPASE ACTIVITY AND COMPOSITIONS SUITABLE FOR PHARMACEUTICAL USE | January 2019 | February 2024 | Allow | 60 | 4 | 2 | No | No |
| 16317432 | METABOLIC DRUG LOADING OF EVs | January 2019 | February 2024 | Abandon | 60 | 5 | 1 | No | No |
| 16317487 | EV-MEDIATED DELIVERY OF BINDING PROTEIN-SMALL MOLECULE CONJUGATES | January 2019 | November 2023 | Abandon | 58 | 5 | 1 | No | No |
| 16239187 | STRAINS AND METHODS FOR ENERGY PARTITIONING IN RUMINANTS | January 2019 | March 2022 | Abandon | 39 | 3 | 0 | No | No |
| 16311321 | DERMATOLOGICAL PREPARATIONS FOR MAINTAINING AND/OR RESTORING HEALTHY SKIN MICROBIOTA | December 2018 | February 2022 | Abandon | 38 | 2 | 1 | Yes | No |
| 16220778 | MATRICES AND METHODS FOR STORAGE AND STABILIZATION OF BIOLOGICAL SAMPLES COMPRISING VIRAL RNA | December 2018 | December 2024 | Abandon | 60 | 4 | 1 | No | No |
| 16308212 | Reduction of Phospholipids in Phospholipid-Containing Oil Material | December 2018 | December 2024 | Abandon | 60 | 5 | 1 | No | Yes |
| 16203731 | METHOD AND TOPICAL COMPOSITION FOR MODIFICATION OF A SKIN MICROBIOME | November 2018 | June 2022 | Abandon | 43 | 4 | 0 | Yes | No |
| 16190402 | METHODS FOR EXTRACELLULAR VESICLE ISOLATION AND SELECTIVE REMOVAL | November 2018 | August 2020 | Allow | 21 | 1 | 0 | Yes | No |
| 16099614 | FOLLICULAR FLUID | November 2018 | December 2021 | Abandon | 37 | 1 | 1 | No | No |
| 16154922 | NANOPARTICLE TARGETED DRUG DELIVERY TO THE LUNGS USING EXTRA-TESTICULAR SERTOLI CELLS | October 2018 | November 2020 | Abandon | 25 | 1 | 0 | No | No |
| 16139741 | COMPOSITIONS AND METHODS COMPRISING BACTERIA FOR IMPROVING BEHAVIOR IN NEURODEVELOPMENTAL DISORDERS | September 2018 | July 2021 | Abandon | 33 | 1 | 1 | No | No |
| 16128009 | PROCEDURE FOR THE PRODUCTION OF A MULTIPLIER AND MODULATOR ADDITIVE OF THE RUMINAL MICROBIOTE | September 2018 | April 2021 | Allow | 31 | 1 | 1 | Yes | No |
| 16081741 | THERAPEUTIC TARGETS FOR LIN-28-EXPRESSING CANCERS | August 2018 | January 2023 | Abandon | 53 | 4 | 1 | No | No |
| 16118874 | HEMATOPOIETIC CELL PHENOTYPING USING CIRCULATING CELL-FREE MARKERS | August 2018 | July 2023 | Allow | 58 | 7 | 0 | Yes | No |
| 16056746 | FERMENTATION METHOD | August 2018 | September 2020 | Abandon | 26 | 0 | 1 | No | No |
| 16074251 | METHOD FOR THE PROTEIN ENRICHMENT OF MICROALGAL BIOMASS | July 2018 | July 2022 | Allow | 47 | 3 | 0 | Yes | No |
| 16037973 | PROCESS FOR THE PURIFICATION OF HYALURONIC ACID | July 2018 | September 2021 | Allow | 38 | 2 | 1 | Yes | No |
| 16013510 | HEMOSTATIC PRODUCTS | June 2018 | April 2021 | Abandon | 34 | 2 | 1 | No | No |
| 16063697 | LIQUID PLATELET-RICH FIBRIN AS A CARRIER SYSTEM FOR BIOMATERIALS AND BIOMOLECULES | June 2018 | December 2022 | Abandon | 54 | 3 | 1 | Yes | No |
| 16063141 | COATING METHOD OF LACTIC ACID BACTERIA WITH INCREASED INTESTINAL SURVIVAL RATE | June 2018 | December 2021 | Abandon | 42 | 3 | 0 | No | No |
| 15778358 | MICROSCAFFOLD | May 2018 | January 2022 | Abandon | 44 | 3 | 1 | No | No |
| 15980337 | COMPOSITIONS FOR TREATING AN ARTHRITIC CONDITION | May 2018 | June 2020 | Abandon | 25 | 0 | 1 | No | No |
| 15759915 | Novel Lactobacillus Having Various Functions, and Use Thereof | March 2018 | March 2021 | Allow | 36 | 2 | 0 | No | No |
| 15908846 | BIOLOGICAL INDICATORS | March 2018 | October 2023 | Abandon | 60 | 6 | 0 | No | No |
| 15903070 | SULFATED ALGINATE HYDROGELS FOR CELL CULTURE AND THERAPY | February 2018 | December 2020 | Allow | 34 | 2 | 1 | Yes | No |
| 15743893 | Cryopreserving Ungulate Embryos | January 2018 | November 2021 | Allow | 46 | 3 | 1 | Yes | No |
| 15743641 | GLYCOSYLATED OXALATE DECARBOXYLASE AND PREPARATION AND APPLICATION THEREOF | January 2018 | June 2021 | Allow | 41 | 2 | 1 | Yes | No |
| 15855664 | METHOD FOR REDUCING METHANE PRODUCTION IN A RUMINANT ANIMAL | December 2017 | July 2020 | Abandon | 30 | 1 | 1 | No | No |
| 15843622 | ALCOHOLIC FERMENTATION PROCESS IN THE PRESENCE OF A HIGH ALCOHOL TOLERANT YEAST AND A MALTOTRIOSE POSITIVE YEAST | December 2017 | June 2020 | Abandon | 30 | 1 | 0 | No | No |
| 15575489 | Method for Dedifferentiating and Culturing Microbial Species | November 2017 | June 2022 | Abandon | 55 | 4 | 1 | Yes | No |
| 15793300 | MUSCLE-POWERED BIOLOGICAL MACHINES | October 2017 | September 2020 | Allow | 35 | 1 | 1 | Yes | No |
| 15793917 | SYNBIOTIC COMPRISING MIRACLE FRUIT AND PROBIOTICS, TABLET THEREOF, AND METHOD FOR PREPARING THE SAME | October 2017 | June 2021 | Abandon | 44 | 3 | 1 | Yes | No |
| 15568820 | COMPOSITIONS COMPRISING YEAST CELLS AND POLYPHENOLS AND THEIR USE | October 2017 | December 2022 | Abandon | 60 | 3 | 1 | No | No |
| 15685509 | ANTIMICROBIAL COMPOSITIONS | August 2017 | September 2021 | Allow | 49 | 3 | 1 | Yes | No |
| 15659300 | METHODS OF RECOVERING OIL FROM MICROORGANISMS | July 2017 | April 2020 | Allow | 33 | 1 | 0 | Yes | No |
| 15632619 | METHODS AND COMPOSITIONS FOR THE DETECTION OF FUNCTIONAL CLOSTRIDIUM DIFFICILE TOXINS | June 2017 | November 2020 | Abandon | 40 | 1 | 1 | No | No |
| 15590668 | METHODS OF TREATING ERECTILE DYSFUNCTION | May 2017 | January 2021 | Abandon | 45 | 2 | 1 | No | No |
| 15524982 | Preparation of tyndallized, intact and immunologically active cells of Lactobacillus rhamnosus GG and method for qualitative and quantitative determination thereof | May 2017 | August 2021 | Abandon | 51 | 3 | 1 | No | Yes |
| 15466226 | BIOLOGICAL PRODUCT FOR CLEARING OF WATER, INDUSTRIAL WASTEWATER AND SOIL FROM CHEMICALS, WHICH ARE RESISTANT TO DEGRADATION AND METHOD FOR USING THE SAME | March 2017 | June 2020 | Abandon | 38 | 1 | 1 | No | No |
| 15440888 | SYSTEM AND METHOD FOR IN VITRO BLOOD VESSEL MODELING | February 2017 | February 2020 | Allow | 35 | 1 | 0 | Yes | No |
| 15440102 | Histological Specimen Treatment | February 2017 | February 2020 | Allow | 36 | 2 | 0 | Yes | No |
| 15429629 | TREATING MYELIN DISEASES WITH OPTIMIZED CELL PREPARATIONS | February 2017 | January 2022 | Allow | 59 | 4 | 1 | No | No |
| 15502100 | VAGINAL COMPOSITION FOR THE TREATMENT OF UROGENITAL INFECTIONS | February 2017 | March 2020 | Abandon | 37 | 2 | 1 | No | No |
| 15424101 | METHOD FOR SORTING NUCLEATED RED BLOOD CELL | February 2017 | December 2019 | Abandon | 34 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GOUGH, TIFFANY MAUREEN.
With a 4.8% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 4.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner GOUGH, TIFFANY MAUREEN works in Art Unit 1651 and has examined 418 patent applications in our dataset. With an allowance rate of 29.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 46 months.
Examiner GOUGH, TIFFANY MAUREEN's allowance rate of 29.7% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by GOUGH, TIFFANY MAUREEN receive 2.73 office actions before reaching final disposition. This places the examiner in the 76% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by GOUGH, TIFFANY MAUREEN is 46 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +53.7% benefit to allowance rate for applications examined by GOUGH, TIFFANY MAUREEN. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 8.4% of applications are subsequently allowed. This success rate is in the 5% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 24.5% of cases where such amendments are filed. This entry rate is in the 34% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 53.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 47% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 40.0% of appeals filed. This is in the 8% percentile among all examiners. Of these withdrawals, 71.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 65.3% are granted (fully or in part). This grant rate is in the 69% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 2.2% of allowed cases (in the 76% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.6% of allowed cases (in the 68% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.